Xenetic Biosciences, Inc. Aktie News

Die Transaktion soll ein an der Nasdaq gelistetes, klinisch fortgeschrittenes Unternehmen mit mehreren Indikationen schaffen, das sich auf die gezielte Bekämpfung neutrophiler extrazellulärer Netzwerke (NETs) fokussiert, einen Treiber von Erkrankungen in der Intensivmedizin, Autoimmunerkrankungen, Transplantation und Onkologie Der Zusammenschluss der beiden Unternehmen vereint Santersus' Nucleo...

Erweiterte gemeinsame Forschungsinitiativen stärken die langfristige Entwicklungsstrategie des Unternehmens für DNase Andauernde Generierung translationaler Daten, die die zukünftige klinische Entwicklung unterstützen und das Verständnis der DNase‑I‑vermittelten NET‑Zielgerichtetheit vertiefen Laufende Lizenzgebühren generieren wiederkehrende, nicht verwässernde Mittel zur Unterstützung weitere...

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion  Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers Inv...

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models Findings support continued clinical development of DNase I as a combinatorial strategy to...

Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty revenue growth Ended first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder value FRAMINGHAM, MA / ACCESS Newswire / M...

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, takin...